HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Thalidomide: current and potential clinical applications.

Abstract
More than three decades after its withdrawal from the world marketplace, thalidomide is attracting growing interest because of its reported immunomodulatory and anti-inflammatory properties. Current evidence indicates that thalidomide reduces the activity of the inflammatory cytokine tumor necrosis factor (TNF)-alpha by accelerating the degradation of its messenger RNA. Thalidomide also inhibits angiogenesis. Recently, the drug was approved for sale in the United States for the treatment of erythema nodosum leprosum, an inflammatory complication of Hansen's disease. However, it has long been used successfully in several other dermatologic disorders, including aphthous stomatitis, Behçet's syndrome, chronic cutaneous systemic lupus erythematosus, and graft-versus-host disease, the apparent shared characteristic of which is immune dysregulation. Many recent studies have evaluated thalidomide in patients with human immunodeficiency virus (HIV) infection; the drug is efficacious against oral aphthous ulcers, HIV-associated wasting syndrome, HIV-related diarrhea, and Kaposi's sarcoma. To prevent teratogenicity, a comprehensive program has been established to control access to the drug, including registration of prescribing physicians, dispensing pharmacies, and patients; mandatory informed consent and education procedures; and limitation of the quantity of drug dispensed. Clinical and, in some patients, electrophysiologic monitoring for peripheral neuropathy is indicated with thalidomide therapy. Other adverse effects include sedation and constipation. With appropriate safeguards, thalidomide may benefit patients with a broad variety of disorders for which existing treatments are inadequate.
AuthorsL Calabrese, A B Fleischer
JournalThe American journal of medicine (Am J Med) Vol. 108 Issue 6 Pg. 487-95 (Apr 15 2000) ISSN: 0002-9343 [Print] United States
PMID10781782 (Publication Type: Journal Article, Review)
Chemical References
  • Angiogenesis Inhibitors
  • Anti-HIV Agents
  • Dermatologic Agents
  • Immunosuppressive Agents
  • Leprostatic Agents
  • Teratogens
  • Thalidomide
Topics
  • Angiogenesis Inhibitors (immunology, pharmacology, therapeutic use)
  • Anti-HIV Agents (immunology, pharmacology, therapeutic use)
  • Arthritis, Rheumatoid (drug therapy)
  • Behcet Syndrome (drug therapy)
  • Dermatologic Agents (immunology, pharmacology, therapeutic use)
  • Ectromelia (chemically induced)
  • Erythema Nodosum (drug therapy)
  • Graft vs Host Disease (drug therapy)
  • HIV Infections (drug therapy)
  • Humans
  • Immunosuppressive Agents (immunology, pharmacology, therapeutic use)
  • Leprostatic Agents (immunology, pharmacology, therapeutic use)
  • Leprosy, Lepromatous (drug therapy)
  • Lupus Erythematosus, Cutaneous (drug therapy)
  • Neoplasms (drug therapy)
  • Peripheral Nervous System Diseases (chemically induced)
  • Stomatitis, Aphthous (drug therapy)
  • Teratogens
  • Thalidomide (immunology, pharmacology, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: